{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:13:41Z","timestamp":1787163221673,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T00:00:00Z","timestamp":1375228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2369-14-165","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T06:14:33Z","timestamp":1375251273000},"source":"Crossref","is-referenced-by-count":22,"title":["Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Jelena","family":"Klawitter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iram","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost","family":"Klawitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Klepacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice Y","family":"Gitomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Schrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Christians","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,31]]},"reference":[{"issue":"9","key":"597_CR1","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1681\/ASN.2008080882","volume":"20","author":"RW Schrier","year":"2009","unstructured":"Schrier RW: Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2009, 20 (9): 1888-1893. 10.1681\/ASN.2008080882.","journal-title":"J Am Soc Nephrol"},{"key":"597_CR2","first-page":"19","volume":"18","author":"PA Gabow","year":"1989","unstructured":"Gabow PA, Schrier RW: Pathophysiology of adult polycystic kidney disease. Adv Nephrol Necker Hosp. 1989, 18: 19-32.","journal-title":"Adv Nephrol Necker Hosp"},{"issue":"5431","key":"597_CR3","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","volume":"285","author":"K Node","year":"1999","unstructured":"Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999, 285 (5431): 1276-1279. 10.1126\/science.285.5431.1276.","journal-title":"Science"},{"issue":"12","key":"597_CR4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/ni1276","volume":"6","author":"CN Serhan","year":"2005","unstructured":"Serhan CN, Savill J: Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005, 6 (12): 1191-1197. 10.1038\/ni1276.","journal-title":"Nat Immunol"},{"issue":"3","key":"597_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1053\/ajkd.2003.50140","volume":"41","author":"S Bianchi","year":"2003","unstructured":"Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003, 41 (3): 565-570. 10.1053\/ajkd.2003.50140.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"597_CR6","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1093\/ndt\/16.11.2152","volume":"16","author":"MA van Dijk","year":"2001","unstructured":"van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ: Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2001, 16 (11): 2152-2157. 10.1093\/ndt\/16.11.2152.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"597_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0022-5347(01)66010-5","volume":"156","author":"NT Stowe","year":"1996","unstructured":"Stowe NT, Inman SR, Tapolyai M, Brouhard BH, Hodge EE, Novick AC: Lovastatin has direct renal hemodynamic effects in a rodent model. J Urol. 1996, 156 (1): 249-252. 10.1016\/S0022-5347(01)66010-5.","journal-title":"J Urol"},{"issue":"3","key":"597_CR8","doi-asserted-by":"publisher","first-page":"F496","DOI":"10.1152\/ajprenal.00350.2004","volume":"289","author":"JD Imig","year":"2005","unstructured":"Imig JD: Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol. 2005, 289 (3): F496-F503. 10.1152\/ajprenal.00350.2004.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"597_CR9","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1046\/j.1523-1755.2000.00304.x","volume":"58","author":"JK Park","year":"2000","unstructured":"Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schafer O, Lindschau C, Schneider W, et al: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 2000, 58 (4): 1420-1430. 10.1046\/j.1523-1755.2000.00304.x.","journal-title":"Kidney Int"},{"issue":"6","key":"597_CR10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/01.ASN.0000068461.45784.2F","volume":"14","author":"M Tonelli","year":"2003","unstructured":"Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003, 14 (6): 1605-1613. 10.1097\/01.ASN.0000068461.45784.2F.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"597_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.104.517565","volume":"112","author":"M Tonelli","year":"2005","unstructured":"Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, et al: Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005, 112 (2): 171-178. 10.1161\/CIRCULATIONAHA.104.517565.","journal-title":"Circulation"},{"issue":"3","key":"597_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/0272-6386(95)90497-2","volume":"26","author":"RD Gile","year":"1995","unstructured":"Gile RD, Cowley BD, Gattone VH, O'Donnell MP, Swan SK, Grantham JJ: Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis. 1995, 26 (3): 501-507. 10.1016\/0272-6386(95)90497-2.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"597_CR13","doi-asserted-by":"publisher","first-page":"F854","DOI":"10.1152\/ajprenal.00059.2007","volume":"293","author":"I Zafar","year":"2007","unstructured":"Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL: Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol. 2007, 293 (3): F854-F859. 10.1152\/ajprenal.00059.2007.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"597_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/ki.1993.79","volume":"43","author":"BD Cowley Jr","year":"1993","unstructured":"Cowley BD, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, Gattone VH: Autosomal-dominant polycystic kidney disease in the rat. Kidney Int. 1993, 43 (3): 522-534. 10.1038\/ki.1993.79.","journal-title":"Kidney Int"},{"issue":"2","key":"597_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1476-5381.1994.tb13081.x","volume":"112","author":"XC Wu","year":"1994","unstructured":"Wu XC, Richards NT, Michael J, Johns E: Relative roles of nitric oxide and cyclo-oxygenase and lipoxygenase products of arachidonic acid in the contractile responses of rat renal arcuate arteries. Br J Pharmacol. 1994, 112 (2): 369-376. 10.1111\/j.1476-5381.1994.tb13081.x.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"597_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0272-6386(12)80587-7","volume":"15","author":"KP Harris","year":"1990","unstructured":"Harris KP, Purkerson ML, Yates J, Klahr S: Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis. 1990, 15 (1): 16-23.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"597_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/rcm.3331","volume":"22","author":"M Masoodi","year":"2008","unstructured":"Masoodi M, Mir AA, Petasis NA, Serhan CN, Nicolaou A: Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography\/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008, 22 (2): 75-83. 10.1002\/rcm.3331.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"12","key":"597_CR18","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/ijc.25965","volume":"129","author":"J Klawitter","year":"2011","unstructured":"Klawitter J, Gurshtein J, Corby K, Fong S, Tagliaferri M, Quattrochi L, Cohen I, Shtivelman E, Christians U: Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic study. Int J Cancer. 2011, 129 (12): 2945-2957. 10.1002\/ijc.25965.","journal-title":"Int J Cancer"},{"issue":"3","key":"597_CR19","first-page":"619","volume":"41","author":"M Merta","year":"1997","unstructured":"Merta M, Tesar V, Zima T, Jirsa M, Rysava R, Zabka J: Cytokine profile in autosomal dominant polycystic kidney disease. Biochem Mol Biol Int. 1997, 41 (3): 619-624.","journal-title":"Biochem Mol Biol Int"},{"issue":"2","key":"597_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000315859","volume":"32","author":"EY Park","year":"2010","unstructured":"Park EY, Seo MJ, Park JH: Effects of specific genes activating RAGE on polycystic kidney disease. Am J Nephrol. 2010, 32 (2): 169-178. 10.1159\/000315859.","journal-title":"Am J Nephrol"},{"issue":"2","key":"597_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/00041552-200403000-00009","volume":"13","author":"A Sarkis","year":"2004","unstructured":"Sarkis A, Lopez B, Roman RJ: Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr Opin Nephrol Hypertens. 2004, 13 (2): 205-214. 10.1097\/00041552-200403000-00009.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"597_CR22","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1111\/j.1523-1755.2005.00678.x","volume":"68","author":"AA Shamshirsaz","year":"2005","unstructured":"Shamshirsaz AA, Reza Bekheirnia M, Kamgar M, Johnson AM, McFann K, Cadnapaphornchai M, Nobakhthaghighi N, Schrier RW: Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Kidney Int. 2005, 68 (5): 2218-2224. 10.1111\/j.1523-1755.2005.00678.x.","journal-title":"Kidney Int"},{"issue":"5","key":"597_CR23","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1046\/j.1523-1755.2001.0590051654.x","volume":"59","author":"GM Fick-Brosnahan","year":"2001","unstructured":"Fick-Brosnahan GM, Tran ZV, Johnson AM, Strain JD, Gabow PA: Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int. 2001, 59 (5): 1654-1662. 10.1046\/j.1523-1755.2001.0590051654.x.","journal-title":"Kidney Int"},{"issue":"19","key":"597_CR24","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","volume":"119","author":"OM Gutierrez","year":"2009","unstructured":"Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, et al: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009, 119 (19): 2545-2552. 10.1161\/CIRCULATIONAHA.108.844506.","journal-title":"Circulation"},{"issue":"5","key":"597_CR25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1475-097X.2010.00943.x","volume":"30","author":"KS Heffernan","year":"2010","unstructured":"Heffernan KS, Patvardhan EA, Hession M, Ruan J, Karas RH, Kuvin JT: Elevated augmentation index derived from peripheral arterial tonometry is associated with abnormal ventricular-vascular coupling. Clin Physiol Funct Imaging. 2010, 30 (5): 313-317.","journal-title":"Clin Physiol Funct Imaging"},{"issue":"8","key":"597_CR26","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1093\/ndt\/gfq806","volume":"26","author":"KS Heffernan","year":"2011","unstructured":"Heffernan KS, Kuvin JT, Sarnak MJ, Perrone RD, Miskulin DC, Rudym D, Chandra P, Karas RH, Menon V: Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2011, 26 (8): 2515-2521. 10.1093\/ndt\/gfq806.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"597_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2215\/CJN.04140510","volume":"6","author":"V Menon","year":"2010","unstructured":"Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M: Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol. 2010, 6 (1): 7-13.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"597_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1681\/ASN.2007080939","volume":"19","author":"ZG Xu","year":"2008","unstructured":"Xu ZG, Yuan H, Lanting L, Li SL, Wang M, Shanmugam N, Kato M, Adler SG, Reddy MA, Natarajan R: Products of 12\/15-lipoxygenase upregulate the angiotensin II receptor. J Am Soc Nephrol. 2008, 19 (3): 559-569. 10.1681\/ASN.2007080939.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"597_CR29","doi-asserted-by":"publisher","first-page":"F985","DOI":"10.1152\/ajprenal.00181.2002","volume":"283","author":"MA Reddy","year":"2002","unstructured":"Reddy MA, Adler SG, Kim YS, Lanting L, Rossi J, Kang SW, Nadler JL, Shahed A, Natarajan R: Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol. 2002, 283 (5): F985-F994.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11","key":"597_CR30","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/sj.ki.5002192","volume":"71","author":"CM Hao","year":"2007","unstructured":"Hao CM, Breyer MD: Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int. 2007, 71 (11): 1105-1115. 10.1038\/sj.ki.5002192.","journal-title":"Kidney Int"},{"issue":"6","key":"597_CR31","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008, 359 (6): 584-592. 10.1056\/NEJMoa0706130.","journal-title":"N Engl J Med"},{"issue":"23","key":"597_CR32","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, et al: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA : j Am Med Assoc. 2011, 305 (23): 2432-2439. 10.1001\/jama.2011.826.","journal-title":"JAMA : j Am Med Assoc"},{"issue":"12","key":"597_CR33","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1172\/JCI64986","volume":"122","author":"RC Smith","year":"2012","unstructured":"Smith RC, O'Bryan LM, Farrow EG, Summers LJ, Clinkenbeard EL, Roberts JL, Cass TA, Saha J, Broderick C, Ma YL, et al: Circulating alphaKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest. 2012, 122 (12): 4710-4715. 10.1172\/JCI64986.","journal-title":"J Clin Invest"},{"issue":"10","key":"597_CR34","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1681\/ASN.2010121224","volume":"22","author":"J Kendrick","year":"2011","unstructured":"Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, Investigators H: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011, 22 (10): 1913-1922. 10.1681\/ASN.2010121224.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"597_CR35","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, et al: FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011, 121 (11): 4393-4408. 10.1172\/JCI46122.","journal-title":"J Clin Invest"},{"issue":"2","key":"597_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/ki.2010.375","volume":"79","author":"I Pavik","year":"2011","unstructured":"Pavik I, Jaeger P, Kistler AD, Poster D, Krauer F, Cavelti-Weder C, Rentsch KM, Wuthrich RP, Serra AL: Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int. 2011, 79 (2): 234-240. 10.1038\/ki.2010.375.","journal-title":"Kidney Int"},{"issue":"8A","key":"597_CR37","doi-asserted-by":"publisher","first-page":"3C","DOI":"10.1016\/S0002-9149(01)01538-7","volume":"87","author":"HR Brunner","year":"2001","unstructured":"Brunner HR: Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol. 2001, 87 (8A): 3C-9C.","journal-title":"Am J Cardiol"},{"issue":"3","key":"597_CR38","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1161\/01.CIR.95.3.588","volume":"95","author":"JB Laursen","year":"1997","unstructured":"Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG: Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997, 95 (3): 588-593. 10.1161\/01.CIR.95.3.588.","journal-title":"Circulation"},{"issue":"2","key":"597_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1161\/01.HYP.0000153321.13792.b9","volume":"45","author":"T Watanabe","year":"2005","unstructured":"Watanabe T, Barker TA, Berk BC: Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 2005, 45 (2): 163-169. 10.1161\/01.HYP.0000153321.13792.b9.","journal-title":"Hypertension"},{"issue":"8","key":"597_CR40","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1681\/ASN.V1181371","volume":"11","author":"D Wang","year":"2000","unstructured":"Wang D, Iversen J, Strandgaard S: Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2000, 11 (8): 1371-1376.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"597_CR41","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1046\/j.1523-1755.2003.00236.x","volume":"64","author":"D Wang","year":"2003","unstructured":"Wang D, Iversen J, Wilcox CS, Strandgaard S: Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int. 2003, 64 (4): 1381-1388. 10.1046\/j.1523-1755.2003.00236.x.","journal-title":"Kidney Int"},{"issue":"2","key":"597_CR42","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1053\/j.ajkd.2007.09.020","volume":"51","author":"D Wang","year":"2008","unstructured":"Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS: Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2008, 51 (2): 184-191. 10.1053\/j.ajkd.2007.09.020.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"597_CR43","doi-asserted-by":"publisher","first-page":"R195","DOI":"10.1152\/ajpregu.90506.2008","volume":"296","author":"D Wang","year":"2009","unstructured":"Wang D, Strandgaard S, Iversen J, Wilcox CS: Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol. 2009, 296 (2): R195-R200.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1","key":"597_CR44","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1681\/ASN.V131170","volume":"13","author":"JT Kielstein","year":"2002","unstructured":"Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol. 2002, 13 (1): 170-176.","journal-title":"J Am Soc Nephrol"},{"issue":"17","key":"597_CR45","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJM199104253241701","volume":"324","author":"R Clarke","year":"1991","unstructured":"Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991, 324 (17): 1149-1155. 10.1056\/NEJM199104253241701.","journal-title":"N Engl J Med"},{"issue":"6","key":"597_CR46","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1172\/JCI116485","volume":"91","author":"AF Perna","year":"1993","unstructured":"Perna AF, Ingrosso D, Zappia V, Galletti P, Capasso G, De Santo NG: Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest. 1993, 91 (6): 2497-2503. 10.1172\/JCI116485.","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"597_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cca.2008.05.018","volume":"395","author":"A Valli","year":"2008","unstructured":"Valli A, Carrero JJ, Qureshi AR, Garibotto G, Barany P, Axelsson J, Lindholm B, Stenvinkel P, Anderstam B, Suliman ME: Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. Clin Chim Acta. 2008, 395 (1\u20132): 106-110.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"597_CR48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1523-1755.2000.00173.x","volume":"58","author":"AK Cheung","year":"2000","unstructured":"Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000, 58 (1): 353-362. 10.1046\/j.1523-1755.2000.00173.x.","journal-title":"Kidney Int"},{"issue":"7","key":"597_CR49","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1097\/01.ASN.0000069165.79509.42","volume":"14","author":"P Stenvinkel","year":"2003","unstructured":"Stenvinkel P, Pecoits-Filho R, Lindholm B: Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol. 2003, 14 (7): 1927-1939. 10.1097\/01.ASN.0000069165.79509.42.","journal-title":"J Am Soc Nephrol"},{"issue":"25","key":"597_CR50","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMoa021583","volume":"347","author":"G Eknoyan","year":"2002","unstructured":"Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002, 347 (25): 2010-2019. 10.1056\/NEJMoa021583.","journal-title":"N Engl J Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-14-165\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:51:43Z","timestamp":1646221903000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-14-165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,31]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["597"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-14-165","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,31]]},"article-number":"165"}}